• 1
    Jazieh AR, Buncher CR. Racial and age-related disparities in obtaining screening mammography: results of a statewide database. South Med J. 2002;95:11458.
  • 2
    Peek ME, Han JH. Disparities in screening mammography. Current status, interventions and implications. J Gen Intern Med. 2004;19:18494.
  • 3
    Pearlman DN, Rakowski W, Ehrich B, Clark MA. Breast cancer screening practices among black, Hispanic, and white women: reassessing differences. Am J Prev Med. 1996;12:32737.
  • 4
    Chang SW, Kerlikowske K, Napoles-Springer A, Posner SF, Sickles EA, Perez-Stable EJ. Racial differences in timeliness of follow-up after abnormal screening mammography. Cancer. 1996;78:1395402.
  • 5
    Rakowski W, Breen N, Meissner H, et al. Prevalence and correlates of repeat mammography among women aged 55–79 in the Year 2000 National Health Interview Survey. Prev Med. 2004;39:110.
  • 6
    Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries. J Gen Intern Med. 2005;20:3844.
  • 7
    Roetzheim RG, Pal N, Tennant C, et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst. 1999;91:140915.
  • 8
    Elmore JG, Nakano CY, Linden HM, Reisch LM, Ayanian JZ, Larson EB. Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care. 2005;43:1418.
  • 9
    Ayanian JZ, Guadagnoli E. Variations in breast cancer treatment by patient and provider characteristics. Breast Cancer Res Treat. 1996;40:6574.
  • 10
    Payne R, Medina E, Hampton JW. Quality of life concerns in patients with breast cancer: evidence for disparity of outcomes and experiences in pain management and palliative care among African-American women. Cancer. 2003;97:3117.
  • 11
    Joslyn SA. Racial differences in treatment and survival from early-stage breast carcinoma. Cancer. 2002;95:175966.
  • 12
    Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:4956.
  • 13
    Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003;97:13447.
  • 14
    Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:33457.
  • 15
    Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138:907.
  • 16
    Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19:145561.
  • 17
    Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003;81:2131.
  • 18
    Gordon NH. Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev. 2003;22:5565.
  • 19
    Brawley OW. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst. 2002;94:4713.
  • 20
    Chu KC, Tarone RE, Brawley OW. Breast cancer trends of black women compared with white women. Arch Fam Med. 1999;8:5218.
  • 21
    Newman LA, Mason J, Cote D, et al. African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer. 2002;94: 284454.
  • 22
    Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin. 2003;53:34255.
  • 23
    Russell A, Langlois T, Johnson G, Trentham-Dietz A, Remington P. Increasing gap in breast cancer mortality between black and white women. World Med J. 1999;98:379.
  • 24
    Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329:32631.
  • 25
    SmedleyBD, StihAY, NelsonAR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academies Press; 2003.
  • 26
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687717.
  • 27
    Peele PB, Siminoff LA, Xu Y, Ravdin PM. Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decision Making. 2005;25:3017.
  • 28
    Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: GoldMR, SiegelJE, RussellLB, WeinsteinMC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:82134.
  • 29
    Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 3—Estimating probabilities and utilities. Med Decision Making. 1997;17:13641.
  • 30
    VonNeumann J, Morgenstern O. Theory of Games and Economic Behavior. Princeton, NJ: Princeton University Press; 1944.
  • 31
    Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:330217.
  • 32
    Jansen SJ, Kievit J, Nooij MA, et al. Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer. 2001;84:157785.
  • 33
    Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83:80319.
  • 34
    Dow KH, Lafferty P. Quality of life, survivorship, and psychosocial adjustment of young women with breast cancer after breast-conserving surgery and radiation therapy. Oncol Nurs Forum. 2000;27:155564.
  • 35
    Dow KH, Ferrell BR, Leigh S, Ly J, Gulasekaram P. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat. 1996;39:26173.
  • 36
    Ferrell BR, Grant MM, Funk BM, Otis-Green SA, Garcia NJ. Quality of life in breast cancer survivors: implications for developing support services. Oncol Nurs Forum. 1998;25:88795.
  • 37
    Mast ME. Survivors of breast cancer: illness uncertainty, positive reappraisal, and emotional distress. Oncol Nurs Forum. 1998;25:55562.
  • 38
    Kennedy ED, Detsky AS, Llewellyn-Thomas HA, et al. Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease. Med Decision Making. 2000;20:728.
  • 39
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:187986.
  • 40
    Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien BJ. Are health states “timeless”? The case of the standard gamble method. J Clin Epidemiol. 1999;52:104753.
  • 41
    Franic DM, Pathak DS, Gafni A. Are health states “timeless”? A case study of an acute condition: post-chemotherapy nausea and vomiting. J Eval Clin Pract. 2003;9:6982.
  • 42
    Fortin JM, Hirota LK, Bond BE, O'Connor AM, Col NF. Identifying patient preferences for communicating risk estimates: a descriptive pilot study. BMC Med Inform Decision Making. 2001;1:2.
  • 43
    Torrance G. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econom Planning Sci. 1976;10:12936.
  • 44
    Torrance G, Thomas W, Sacket D. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972;7:11833.
  • 45
    Torrance G. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:130.
  • 46
    Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, Ciampi A, Till JE, Boyd NF. The measurement of patients' values in medicine. Med Decision Making. 1982;2:44962.
  • 47
    Redelmeier DA, Heller DN. Time preference in medical decision making and cost-effectiveness analysis. Med Decision Making. 1993;13:2127.
  • 48
    Hoyert D, Arias E, Smith B, Murphy S, Kochanek M. Deaths: final data for 1999. Natl Vital Stat Rep. 2001;49.
  • 49
    Cykert S, Phifer N. Surgical decisions for early stage, non-small cell lung cancer: which racially sensitive perceptions of cancer are likely to explain racial variation in surgery? Med Decision Making. 2003;23:16776.
  • 50
    Bruner DW, Hanlon A, Mazzoni S, et al. Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:3442.
  • 51
    Knight SJ, Siston AK, Chmiel JS, et al. Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer. 2004;3:317.
  • 52
    Tsevat J. What do utilities measure? Med Care. 2000;38:160164.
  • 53
    Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Med Care. 1989;27:S190204.
  • 54
    Bleichrodt H, Johannesson M. The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence. Med Decision Making. 1997;17:2132.
  • 55
    Bleichrodt H, Van Rijn J, Johannesson M. Probability weighting and utility curvature in QALY-based decision making. J Math Psychol. 1999;43:23860.
  • 56
    NCI. Surveillance Epidemiology and End Results (SEER). Cancer Statistics. Available at: Accessed August 30, 2005.